More on SVRA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.3 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Savara (NQ:SVRA)
Delayed: 5.50 +0.12 (2.23%)
Prev. Close $5.38  
Open$5.54 
52 Wk High$ 
52 Wk Low$ 
Day High$5.63 
Day Low$5.37 
P/E N/A  
EPS$ 
Volume4,761,570 

Friends, Peers and Foes (?): HTGC, CRNX, CYTK, MDGL, SLNO (more...)

Jun 12, 2026 04:05 PM Savara Announces New Employment Inducement Grant
Jun 8, 2026 04:16 PM Form 8-K Savara Inc For: Jun 04
Jun 8, 2026 04:05 PM Savara names Robert Lutz as chief operating and financial officer
Jun 8, 2026 04:05 PM Savara Announces Chief Financial and Administrative Officer Transition
May 27, 2026 04:05 PM Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 20, 2026 08:15 AM Savara presents biomarker data from phase 3 trial at ATS conference
May 20, 2026 08:15 AM Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor
May 19, 2026 02:15 PM Savara presents long-term data from molgramostim trial extension
May 19, 2026 02:15 PM Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar
May 18, 2026 02:55 PM Savara reports improved exercise capacity in aPAP drug trial
View All Articles

Entities mentioned with SVRA

View All Entities